etoposid ebewe 20 mg/ ml
ebewe pharma ges.m.b.h nfg. kg - etoposid - konsentrat til infusjonsvæske, oppløsning - 20 mg/ ml
etoposid fresenius kabi 20 mg/ ml
fresenius kabi norge as - etoposid - konsentrat til infusjonsvæske, oppløsning - 20 mg/ ml
photobarr
pinnacle biologics b.v. - porfimer sodium - barretts Øsofagus - antineoplastiske midler - fotodynamisk terapi (pdt) med photobarr er indikert for: ablasjon av høy grad av dysplasi (hgd) hos pasienter med barrett spiserøret (bo).
blincyto
amgen europe b.v. - blinatumomab - forløpercellelymfoblastisk leukemi-lymfom - antineoplastiske midler - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.
sutent
pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiske midler - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.
bendamustine accord 2.5 mg/ ml
accord healthcare b.v. - bendamustinhydrokloridmonohydrat - pulver til konsentrat til infusjonsvæske, oppløsning - 2.5 mg/ ml
bendamustine fresenius kabi 2.5 mg/ ml
fresenius kabi norge as - bendamustinhydroklorid - pulver til konsentrat til infusjonsvæske, oppløsning - 2.5 mg/ ml
cerubidin 20 mg
sanofi-aventis norge (3) - daunorubicinhydroklorid - pulver til infusjonsvæske, oppløsning - 20 mg
fludara 10 mg
genzyme europe b.v. - fludarabinfosfat - tablett, filmdrasjert - 10 mg
fludarabin actavis 25 mg/ ml
actavis group ptc ehf - fludarabinfosfat - konsentrat til injeksjons-/infusjonsvæske, oppløsning - 25 mg/ ml